Drugs / REGN5459
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04083534 | Sep 2019 → May 2025 | plasma cell myeloma | Regeneron Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN5459 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04083534 ↗ |
| Modality | Monoclonal antibody | “Anti-BCMA x Anti-CD3 Bispecific Antibody” NCT04083534 ↗ |
| Route | Intravenous | “Administered by intravenous (IV) infusion” NCT04083534 ↗ |